JDS Therapeutics recognizes the vital role that nurse practitioners play in providing women with holistic, comprehensive care throughout their lives and we are proud to have Dr. Lisa Chism and Dr. Diane Pace join the Relizen Advisory Board.
New York (PRWEB) March 09, 2015
JDS Therapeutics, the maker of Relizen®, a non-hormonal therapy for the relief of hot flashes associated with menopause, is pleased to announce the additions of Dr. Lisa Chism and Dr. Diane Pace to the Relizen Provider Advisory Board. The award-winning therapy is supported by a board of experts in women’s health who have reviewed Relizen’s clinical data.
Diane Pace, PhD, APRN, NCMP, FAANP, Clinical Professor at the University of Memphis Loewenberg School of Nursing, is a family nurse practitioner providing primary care and menopausal health care at the Methodist Teaching Practice, and she is currently teaching in the University of Memphis School of Nursing clinical program in the Family Nurse Practitioner track. Recipient of the 2014 NPWH Inspirations in Women’s Health Award, Dr. Pace was the first nurse practitioner to serve as president of the North American Menopause Society (NAMS) and is a NAMS Certified Menopause Practitioner. Dr. Pace has published on menopause and is a contributor to the NAMS Menopause Practice: A Clinician’s Guide textbooks. She served on the Menopause Curriculum Task Force to develop a curriculum for residents and other clinicians by NAMS and the Association of Professors of Gynecology and Obstetrics (APGO), and serves on the NAMS Scientific Committee, and as a reviewer for the journal of Menopause. She is a Fellow in the American Association of Nurse Practitioners, presents at their national conferences, and was awarded the 2013 AANP Nurse Practitioner State Excellence Award.
Lisa Chism, DNP, APRN, NCMP, FAANP has been a nurse practitioner for more than 22 years, and is currently working at the Karmanos Cancer Institute, where she serves as the Clinical Director of the Women’s Wellness Clinic. Dr. Chism has received a number of accolades in recent years, including the 2013 Karmanos Heroes of Breast Cancer Compassionate Caregiver Award, the 2013 Nightingale Award for Excellence in the Distinguished Alumni of Oakland University, and First Place in Advanced Practice Nursing from the American Journal of Nursing Book of the Year Awards for The Doctor of Nursing Practice: A Guidebook for Role Development and Professional Issues. Dr. Chism has also been highly involved with the North American Menopause Society (NAMS) – she currently serves as Chair of the NAMS Membership Committee and was named the NAMS Menopause Practitioner of the Year in 2011. Dr. Chism is also a NAMS Certified Menopause Practitioner
Michael Satow, President and CEO of JDS Therapeutics, states, “JDS Therapeutics recognizes the vital role that nurse practitioners play in providing women with holistic, comprehensive care throughout their lives and we are proud to have Dr. Lisa Chism and Dr. Diane Pace join the Relizen Advisory Board. Nurse Practitioners are often on the front lines when it comes to helping women cope with menopause. Relizen is a safe and efficacious option for women who want relief from hot flashes without an estrogenic effect. Dr. Chism and Dr. Pace will be incredibly helpful in advising our company on how to better engage with and educate nurses and patients about Relizen.”
Dr. Pace reflected, “There is no one menopausal syndrome, and likewise no one answer to the myriad of ways a woman navigates through this developmental milestone in her life. Some women manage symptoms without any need for interventions, but some women seek out support from their primary care provider to help them find options to manage symptoms affecting their quality of life. As a NAMS Certified Menopause Practitioner, I encourage her to take an active part in the decision-making process, and together we investigate and find the best options for managing her symptoms. Non-hormonal and alternative options are an important topic to fully discuss with women who want or need these options to treat their vasomotor symptoms.”
“Quality of life matters,” says Dr. Chism, “especially when caring for special populations such as women who cannot take hormone therapy due to cancer or other health concerns. Being able to offer women non-hormonal options to treat vasomotor symptoms improves quality of life and gives women peace of mind. It is a privilege to care for this special population especially when I can safely improve their quality of life.”
Dr. Diane Pace and Dr. Lisa Chism join other respected experts in the field of women’s health on the Relizen Board of Advisors, including:
- Rebecca Brightman, MD, NCMP, FACOG, Attending Physician and Assistant Clinical Professor, Mt. Sinai School of Medicine
- David Elia, MD, Gynecologist, Paris, France
- Richard Fain, MD, FACOG, Board Certified OBGYN, West Essex OB/GYN Associates
- Marlene Freeman, MD, Associate Professor of Psychiatry at Harvard Medical School
- Steven Goldstein, MD, CCD, NCMP, FACOG, Professor of Obstetrics and Gynecology at New York University
- Matt T. Rosenberg, MD, Medical Director at Mid-Michigan Centers
- Harvey Schneier, MD, Executive Director of Clinical Development at Forest Research Institute
- Lee Shulman, MD, FACOG, Distinguished Physician at Northwestern Memorial Hospital and Northwestern University
- James Simon, MD, CCD, NCMP, FACOG, Clinical Professor of Obstetrics and Gynecology at George Washington University Hospital
- Kaj Winther, MD, Chief Physician of the Department of Clinical Biochemistry at Frederiksberg Hospital in Denmark
To learn more about Relizen, please visit http://www.Relizen.com.
About JDS Therapeutics
JDS Therapeutics markets proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS is focused on providing patients with scientifically backed, natural approaches to meeting their healthcare needs, and owns more than 100 issued or pending patents worldwide involving clinically active natural compounds. Relizen is a registered trademark of JDS Therapeutics, LLC.